Effectiveness of rituximab biosimilar (Reddytux<sup>®</sup>) on the treatment of diffuse large B-cell lymphoma
Reddytux<sup>®</sup> is an antitumor agent that is a monoclonal antibody against the CD20 transmembrane antigen. The drug is registered in Russian Federation since 2016. Reddytux<sup>®</sup> is the cheapest biosimilar drug containing rituximab, included in the list of vital and most important drugs for medical use. This means that it can be the best-choice medication in the treatment of patients with diffuse large B-cell lymphoma (DLBCL) in complex and monotherapy. No works evaluating the clinical experience of Reddytux® in Russian Federation have been published. We conducted a study on the effectiveness of the use of the Reddytux<sup>®</sup> (rituximab bioanalogue) in patients older than 35 years with DLBCL during immunochemotherapy in the R-CHOP mode. As a control was taken a group of patients who underwent a course of immunochemotherapy in the CHOP mode. It was shown that in the group treated in the R-CHOP regimen (with the inclusion of the Reddytux<sup>®</sup> preparation), the frequency of complete remissions increased, the overall and event-free survival rate, the mortality of patients during treatment decreased, and the number of relapses decreased. In addition, a clinical example of the successful use of R-CHOP therapy with the addition of the Reddytux® preparation is given, which made it possible to achieve complete remission of the disease, confirmed by CT data.